antiplatelet

(redirected from antiplatelet drugs)
Also found in: Medical.
Related to antiplatelet drugs: anticoagulant drugs

an·ti·plate·let

 (ăn′tē-plāt′lĭt, ăn′tī-)
adj.
Acting against or destroying blood platelets.
Mentioned in ?
References in periodicals archive ?
We present a case of gastrointestinal bleeding due to antiplatelet therapy after percutaneous coronary intervention (PCI) and secondary in-stent thrombosis due to discontinuation of antiplatelet drugs.
Background: Antiplatelet drugs are effective in preventing recurrence of atherosclerosis in type 2 diabetic patients.
Aspirin helps prevent platelets in the bloodstream from clumping together and forming a clot, so it is called an antiplatelet drug; other antiplatelet drugs include Clopidogrel (Plavix) and ticagrelor (Brilinta).
Current antiplatelet drugs prevent the clotting cells in the blood called platelets from sticking together, which helps people who have heart disease.
This included 28,583 who were not taking any antithrombotic treatment, 12,751 who were taking subtherapeutic doses of warfarin (international normalized ratio (INR) of less than 2 at the time of their stroke), and 37,674 who were taking only antiplatelet drugs when additional treatment was indicated, the investigators said (JAMA.
Background and Objective: Antiplatelet drugs are frequently used after coronary artery bypass graft (CABG) surgery to prevent venous graft occlusion.
Regarding the use of antithrombotic and antiplatelet drugs, the use of bivalirudin increased and there were decreases in the use of clopidogrel and glycoprotein IIb/IIIa inhibitors between the two time periods.
They concluded that patients taking single or dual antiplatelet drugs may have teeth extracted safely without interruption of treatment using only local haemostatic measures.
Others are likely to be discovered, and some of these non-hemostatic platelet functions can be attenuated with antiplatelet drugs, expanding the applications of these drugs to non-traditional uses.
Another 22% of the patients received lipid-lowering agents and 7% received antiplatelet drugs, which are intended to prevent long-term cardiovascular complications--not beneficial in those with limited life expectancy, the researchers said (JAMA Intern.